Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Smarttech247 extends contract with major Irish hospital

(Sharecast News) - Smarttech247 announced a significant contract extension with an unnamed major hospital in Ireland on Monday, valued at about €0.5m over four years. The AIM-traded firm said the agreement would build on an existing relationship, and involve the integration of an advanced endpoint detection and response (EDR) solution into the hospital's existing VisionX managed detection and response (MDR) platform.

It said the enhanced cybersecurity deployment would strengthen the hospital's defences, delivering real-time threat detection, faster incident response and improved protection of critical systems and sensitive patient data.

The contract extension reflected growing demand for robust cybersecurity in the healthcare sector, the board explained, where operational resilience and data protection were being increasingly prioritised.

"This win is further validation of our VisionX MDR offering and our capability to deliver enterprise-grade cybersecurity solutions tailored to high-impact environments like healthcare," said chief executive officer Raluca Saceanu.

"We're proud to be supporting one of Ireland's leading hospitals in strengthening its cyber resilience."

Saceanu said the latest success strengthened Smarttech247's growing footprint in the healthcare sector, and reinforced its position as a "trusted cybersecurity partner".

"Importantly, the win also reflects our continued successful execution of our 2025 strategy, which focuses on increasing total contractual value through effective upselling and cross-selling across Smarttech247's suite of cybersecurity solutions."

At 1312 GMT, shares in Smarttech247 were down 1.69% at 7.25p.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.